Background: Glycogen storage disease (GSD) 
Background and Aims
Glycogen storage disease type III (GSD III) also known as Cori disease, is a part of a rare group of inherited enzyme defects that affect the glycogen metabolism to produce glucose. It is an inborn error of metabolism caused by autosomal recessive deficiency in glycogen disbranching enzymes [1] . It is a disease of variable clinical severity affecting primarily the liver and muscle tissue. Internationally, the frequency and incidence GSD III is 1 children per 100,000 live births [2] [3] [4] . Deficiency of the enzyme in liver and muscle tissue produces a variant known as GSD IIIa which is more common, whereas the GSD IIIb is another variant caused by a deficiency of the enzyme in the liver only without muscle involvement [1, 5] .
The GSD III shows diverse clinical presentations. In infancy and early childhood, it presents with recurrent infection, hypoglycemia, hepatomegaly and growth retardation is not unexpected [5] . On the other hand, during adulthood, it presents only with asymptomatic hepatomegaly, myopathy or occult liver disease [6] . In a small portion of patients with GSD III end stage liver disease or cirrhosis may occur due to chronic fibrosis [7] [8] [9] . Generally, fasting hypoglycemia improves with age and hepatomegaly frequently regresses [10] [11] .
Case presentation
In this case study, acute management of the child is beyond the scope of this case however, medical-nutritional intervention of GSD IIIa was evaluated by retrograde reviewing the BMI, blood and biochemical tests on presentation and a month later visit for a 2-year-old Jordanian male who is known to have a GSD IIIa since he was 4 months. His parents are relatives with no known family history of GSD IIIa. He had been breastfed for 4 months. The child is on a special diet (small, frequent meals of complex carbohydrates and protein, avoiding simple sugars and fasting is prohibited). The child showed good activity level and a good appetite. The child's parents are eager to compresence and learn more about their child's case from nutritional point of view so they referred to department of clinical nutrition to know more about their child rare disease.
The weight and height were reported by the child's parents (11.3 Kg and 98 cm) respectively. A series of biochemical tests that conducted during hospitalization including Urea, Creatinine, Cholesterol, Triglycerides, Albumin, total Bilirubin, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT). Moreover, the blood test included Hemoglobin, WBCs and RBCs. A written informed consent was obtained from child parents after the nature of the case study had been explained. The biochemical tests on presentation and on a month later visit after nutritional intervention are given in Table 2 . The following biochemical tests were different after nutritional intervention: Random blood glucose (62 mg/dl vs. 77 mg/dl), Urea (50 mg/dl vs. 19 mg/dl), Creatinine (0.9 mg/dl vs. 0.5 mg/dl), Cholesterol (260 mg/dl vs. 143 mg/dl), Triglycerides (243mg/dl vs. 171mg/dl), Albumin (3.7 g/dl vs. 3.3 g/dl) and Bilirubin total (0.67 mg/dl vs. 0.5 mg/dl). The Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) were also lower after nutritional intervention (790 U/L vs. 226 U/L) and (239 U/L vs. 133 U/L) respectively. As shown above, the child had hypercholesterolemia and hypertriglyceridemia on presentation. Table 2 . The biochemical test on presentation and one month later after nutritional intervention. This is consistent with other studies results, where 40% of those with GSD III have hyperlipidemia [15, 16] . However, not all studies confirm this finding [17] . The hypertriglyceridemia and hypercholesterolemia were correlated negatively with age, and may reflect increased severity of hypoglycemia in this younger population [18] [19] [20] . The child urea and creatinine level were typically normal on presentation.
Normal range
Whereas, elevated hepatic transaminase concentrations with more than 500 U/L aspartate aminotransferase (AST) concentrations were also observe [3, 20] . Although Serum level of AST and ALT are markedly elevated in the first decade of life, it tends to decrease significantly thereafter [5] . In general, Hepatomegaly among individuals with GSD III may improve with age and usually resolve after puberty [3] . All previous biochemical tests were improved after one month of medical-nutritional therapy which aimed to decrease the workload of the liver by providing a diet with lower simple sugar, high in complex carbohydrate and protein and normal fat with bedtime snack and cornstarch to enhance gluconeogenesis and prevent hypoglycemia. Follow up every 6 months of serum AST, ALT, bilirubin and albumin to yearly detect the extent of hepatic damage monitor progression of liver failure and routine immunizations should be offered including hepatitis B [3] . The plan of medical-nutritional intervention of GSD IIIa in general should be individualized, no specific therapy exists. However, it is mainly based on symptomatic and nutritional therapies.
Conclusion
These results emphasize the importance of the collaboration among multidisciplinary medical care professionals including clinical nutritionist; to establish an individualized medical-nutritional intervention in children of GSD IIIa to ensure the patients best care and outcome.
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